EBITDA Margin % is calculated as EBITDA divided by its Revenue. Graphite Bio's EBITDA for the
three
months ended in Dec. 2023 was $-14.46 Mil. Graphite Bio's Revenue for the
three
months ended in Dec. 2023 was $0.00 Mil. Therefore, Graphite Bio's EBITDA margin for the quarter that ended in Dec. 2023 was 0.00%.
Graphite Bio EBITDA Margin % Historical Data
The historical data trend for Graphite Bio's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Graphite Bio's EBITDA Margin %
For the Biotechnology subindustry, Graphite Bio's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Graphite Bio's EBITDA Margin % Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Graphite Bio's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Graphite Bio's EBITDA Margin % falls into.
Graphite Bio EBITDA Margin % Calculation
EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.
Graphite Bio's EBITDA Margin % for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Graphite Bio (NAS:GRPH) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Graphite Bio EBITDA Margin % Related Terms
Thank you for viewing the detailed overview of Graphite Bio's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.
Graphite Bio Inc is a clinical-stage gene-editing company harnessing gene integration to develop a new class of therapies to cure serious and life-threatening diseases. Its gene-editing platform allows to precisely correct mutations, replace entire disease-causing genes with normal genes, or insert new genes into predetermined, safe locations. Its product candidate GPH101 is a differentiated approach with the potential to directly correct the mutation that causes sickle cell disease (SCD) and restore normal adult hemoglobin (HgbA) expression. All of the company's long-lived assets are based in the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
GRPH has been successfully added to your 